639 related articles for article (PubMed ID: 33106987)
21. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.
Tan HW; Xu YM; Lau ATY
Rev Med Virol; 2020 Sep; 30(5):e2122. PubMed ID: 32602627
[TBL] [Abstract][Full Text] [Related]
23. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
[TBL] [Abstract][Full Text] [Related]
24. Why are ACE2 binding coronavirus strains SARS-CoV/SARS-CoV-2 wild and NL63 mild?
Rawat P; Jemimah S; Ponnuswamy PK; Gromiha MM
Proteins; 2021 Apr; 89(4):389-398. PubMed ID: 33210300
[TBL] [Abstract][Full Text] [Related]
25. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
26. Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2.
Mathewson AC; Bishop A; Yao Y; Kemp F; Ren J; Chen H; Xu X; Berkhout B; van der Hoek L; Jones IM
J Gen Virol; 2008 Nov; 89(Pt 11):2741-2745. PubMed ID: 18931070
[TBL] [Abstract][Full Text] [Related]
27. A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics.
Verma J; Subbarao N
Arch Virol; 2021 Mar; 166(3):697-714. PubMed ID: 33483791
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2, ACE2 expression, and systemic organ invasion.
Ashraf UM; Abokor AA; Edwards JM; Waigi EW; Royfman RS; Hasan SA; Smedlund KB; Hardy AMG; Chakravarti R; Koch LG
Physiol Genomics; 2021 Feb; 53(2):51-60. PubMed ID: 33275540
[TBL] [Abstract][Full Text] [Related]
29. The spike protein of SARS-CoV--a target for vaccine and therapeutic development.
Du L; He Y; Zhou Y; Liu S; Zheng BJ; Jiang S
Nat Rev Microbiol; 2009 Mar; 7(3):226-36. PubMed ID: 19198616
[TBL] [Abstract][Full Text] [Related]
30. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.
Heurich A; Hofmann-Winkler H; Gierer S; Liepold T; Jahn O; Pöhlmann S
J Virol; 2014 Jan; 88(2):1293-307. PubMed ID: 24227843
[TBL] [Abstract][Full Text] [Related]
31. The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise.
Joseph S; Nair B; Nath LR
Curr Mol Med; 2021; 21(10):888-913. PubMed ID: 33563197
[TBL] [Abstract][Full Text] [Related]
32. Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability Utilizing Natural Agents.
Nandi S; Roy H; Gummadi A; Saxena AK
Curr Drug Targets; 2021; 22(17):2006-2020. PubMed ID: 33687893
[TBL] [Abstract][Full Text] [Related]
33. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
34. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
Brown EEF; Rezaei R; Jamieson TR; Dave J; Martin NT; Singaravelu R; Crupi MJF; Boulton S; Tucker S; Duong J; Poutou J; Pelin A; Yasavoli-Sharahi H; Taha Z; Arulanandam R; Surendran A; Ghahremani M; Austin B; Matar C; Diallo JS; Bell JC; Ilkow CS; Azad T
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668756
[TBL] [Abstract][Full Text] [Related]
36. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
Rohilla S
Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
38. Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection.
Delgado-Roche L; Mesta F
Arch Med Res; 2020 Jul; 51(5):384-387. PubMed ID: 32402576
[TBL] [Abstract][Full Text] [Related]
39. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method.
Lim H; Baek A; Kim J; Kim MS; Liu J; Nam KY; Yoon J; No KT
Sci Rep; 2020 Oct; 10(1):16862. PubMed ID: 33033344
[TBL] [Abstract][Full Text] [Related]
40. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
Jokinen EM; Gopinath K; Kurkinen ST; Pentikainen OT
IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1281-1289. PubMed ID: 33914685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
